Answers are grounded in this paper and cite their sources.
Retrospective analysis shows hepatic steatosis may not harm outcomes in living donor liver transplantation, suggesting revised donor selection criteria.
In carefully selected donors, mild to moderate hepatic steatosis may not be associated with adverse posttransplant outcomes in LDLT. Incorporating such donors may safely expand the donor pool amid the growing MASLD epidemic. Prospective studies are needed to further refine donor selection criteria.
No takes yet. Share an insight, caveat, or question.
Jadaun et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: